| Trial ID: | L6700 |
| Source ID: | NCT02949193
|
| Associated Drug: |
Evogliptin
|
| Title: |
Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: evogliptin|DRUG: Sitagliptin
|
| Outcome Measures: |
Primary: HbA1c, unit: %, Change from baseline at 24 week | Secondary: fasting plasma glucose, unit : mg/dL, Change from baseline at 24 week|HOMA-beta, unit: %, Change from baseline at 24 week|HbA1c response rate, unit: %, Change from baseline at 24 weeks
|
| Sponsor/Collaborators: |
Sponsor: Dong-A ST Co., Ltd.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
222
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2013-05
|
| Completion Date: |
2015-05
|
| Results First Posted: |
|
| Last Update Posted: |
2016-10-31
|
| Locations: |
Kangbuk Samsung Medical Center, Seoul, 110-746, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT02949193
|
